Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma

Annals of Oncology

Volumn 12, Issue 4, 2001, Pages 519-524

  Martoni, A ^a   Mini, E ^b   Pinto, C ^a   Nobili, S ^b   Gentile, A L ^a   Dentico, P ^b   Angelelli, B ^a   Scicolone, S ^b   Piana, E ^a   Mazzei, T ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

5 Fluorouracil; Colorectal carcinoma; Oxaliplatin; Protracted i.v. infusion

Indexed keywords

FLUOROURACIL; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INFUSION PUMP; MALE; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE;

EID: 0035012048     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011103213297     Document Type: Article

References (18)

1. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rata. J Clin Oncol 1992; 10: 896-903.
2. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with a convential bolus schedule in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425-33.
3. Meta-Analysis Group in Cancer. Toxicity of fluoroyuracil in patients with advanced colorectal cancer: Effects of administration schedule and prognosic factors. J Clin Oncol 1998; 16: 3537-41.
4. Falcone A, Allegrini G, Lencioni M et al. Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolusbased chemotherapy: A phase II study. Cancer Chemother Pharmacol 1999; 44 (2): 159-63.
5. Lévi F, Perpoint B, Garufi C et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of five-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 9: 1280-4 (Abstr 29).
6. Machover D. Diaz-Rubio E, de Gramont A et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropirymidines. Ann Oncol 1996; 7: 95-8.
7. Mathé G, Kidani Y, Segiguchi M et al. Oxalato-platinum or L-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cisplatinum and carboplatinum. Biomed Pharmacother 1989; 43: 237-50.
8. Tashiro T, Kawada Y, Sakurai Y et al. Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diamino-ciclohexane) platinum (II), new experimental data. Biomed Phamacother 1989; 43: 251-60.
9. Lévi F, Misset JL, Brienza S et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69: 893-900.
10. Garufi C, Brienza S, Bensmaine MA et al. Addition of oxaliplatin (L-OHP) to chronomodulated (CM) 5-fluorouracil (5-FU) and folinic acid (FA) for reversal of acquired chemoresistance in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1995; 14: 192A.
11. De Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214-9.
12. André T, Bensmaine MA, Louvet C et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion and oxaliplatin for colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17: 3560-8.
13. Maindrault-Goebel F, Louvet C, André T et al. Oxaliplatin added to the simplified bimonthly Leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOL-FOX 6). Eur J Cancer 1999; 35: 1338-42.
14. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
15. Diaz Rubio E, Sastre J, Zaniboni A et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann Oncol 1998; 9: 105-8.
16. Becouarn Y, Ychou M, Ducreux M et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998; 16: 2739-44.
17. De Gramont A, Figer A, Seymour M et al. Leucovorin and Fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
18. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47.